International Collaboration in FP7 Health Research Dr. Indridi Benediktsson Directorate Health Horizontal Aspects and Coordination

Reminder: ALL RESEARCH TOPICS WERE OPEN FOR 3rd COUNTRY PARTICIPANTS Outcome of FP6 Reminder: ALL RESEARCH TOPICS WERE OPEN FOR 3rd COUNTRY PARTICIPANTS At least 3 organizations from EU and/or associated states In addition, “third country” participants were welcome Partners from the INCO target countries, could receive funding

Outcome of FP6 € 2.4 billion for health research; 604 projects over the 4 years Average success rate: 25.4% Total number of participants: 7,426 Project type number av. EC contribution partners Integrated Projects 119 € 10.0m 21 Networks of Excellence 40 € 9.3m 30 STRePs 322 € 2.2m 8 Coordination Actions 25 € 1.1m 19 Specific Support Actions 98 € 0.4m 6

3rd countries’ participation in FP6 Health Research Number of 3rd country participants in Health projects Number of participants (Top Ten) In total: 245 participants from 51 third countries

Timeframe for FP7 projects Results from FP7 projects in use Projects resulting from FP7 calls operating Official duration of FP7 2007-2013 2012 2006 2007 2014 2008 2009 2010 2015 2011 2013 2016 2017 2018 2019 2020 2021 First calls First projects start Last projects start Last projects end

Cooperation – Collaborative Research Nine themes Health Food, agriculture, fisheries and biotechnology Information and communication technologies Nanosciences, nanotechnologies, materials and new production technologies Energy Environment (including climate change) Transport (including aeronautics) Socio-economic sciences and the humanities Security and space Euratom: Fusion energy research, nuclear fission and radiation protection +

Collaborative Research changing priorities (relative weight) FP1 FP2 FP3 FP4 FP5 FP6 Socio -economic Transport Environment Industrial + materials tech. ICT Energy Life Sciences* FP7 Security + Space *from FP6 split into: Health + Food/Agri/Biotech

Health Research Objectives: Improving the health of European citizens Increasing the competitiveness of European health-related industries and business Addressing global health issues including emerging epidemics

+ Health Research Rationale for pan-European approach (I): Sequencing of human genome advances in post-genomics vast amount of data, accelerated discovery Translational research multidisciplinary Health policy-driven research comparisons of national models & data + Rationale for pan-EU approaches (I): Sequencing of human genome and recent advances in post-genomics  vast amounts of data Translational research (translation of basic discoveries in clinical applications)  multidisciplinarity Health policy-driven research  comparisons of the national models & data

Health Research Rationale for pan-European approach (II): Strong EU-based biomedical research strengthen the competitiveness of large industries (pharma) and SMEs (healthcare biotech & medical technology) Transnational co-operation is essential to face the worldwide competition Contribute to the development of norms & standards to set up appropriate legislative framework for new medical technologies (e.g. regenerative medicine)

1. Health Three pillars of activities: Budget: €6 billion over 7 years (2007-2013) Three pillars of activities: Biotechnology, generic tools and technologies for human health Translating research for human health Optimising the delivery of healthcare to European citizens

Collaborative research in Health 1: Biotechnology, generic tools and technologies High-throughput research (enhancing data generation, standardisation, acquisition & analysis) Detection, diagnosis and monitoring (with emphasis on non-invasive or minimally invasive approaches) Innovative therapeutic approaches and interventions (with potential application in many diseases and disorders) Predicting suitability, safety and efficacy of therapies (biological markers, in vivo and in vitro methods and models, simulation, pharmacogenomics, targeting etc.)

Collaborative research in Health 2: Translating research for human health Integrating biological data and processes: (large-scale data gathering, systems biology) Research on the brain and neurological diseases, human development and ageing Infectious diseases: to confront major threats to public health (antimicrobial drug resistance, HIV/AIDS, malaria, TB, emerging epidemics, NID) Other major diseases: (cancer, cardiovascular disease, diabetes/obesity; rare diseases; and other chronic diseases)

Collaborative research in Health 3: Optimising the delivery of health care Enhanced health promotion and disease prevention (providing evidence of best public health measures – life styles, interventions, special focus on mental health etc.) Translating clinical research into clinical practice (patient safety, better use of medicines, benchmarking etc.) Quality, solidarity and sustainability of health systems (organisational and financial aspects, health systems etc.)

European Technology Platform The Innovative Medicines Initiative

Creating new medicines is a high risk journey 15 10 5 Idea Medicine years The problem is global and very complex The situation is unsustainable We need new creative approaches Some initiatives has been presented here today

The Innovative Medicines Initiative Starting point: drug development: increasing cost, duration and risk competitiveness of pharmaceutical industry affected EU concerned by loss of leadership in pharma R&D Response: the Innovative Medicines Initiative collaborative effort between EC and pharmaceutical industry (EFPIA) tackle specific issues where research is the key Public Private Partnership for implementation

Calls for proposals in 2007 Health theme First calls for proposals issued 22 Dec.’06 first deadline: 19 April 2007 €628 million second deadline: 18 September 2007 €532 million1 [ not all areas will be open in each call ] 1: pending approval of 2008 budget

Evaluation Peer review by invited experts Criteria: S+T quality -of the concept, objectives and methodology Impact -potential impact, dissemination, exploitation, use Implementation -management, quality of consortium, resources

International Collaboration -issues at stake: Development assistance policy objectives, e.g. Millennium Development Goals targets: poor countries, e.g. ACP Strengthening EU competitiveness competing with industrialised countries (e.g. attracting excellence) collaboration for mutual gains targets: more developed countries (e.g. BRIC) Science diplomacy collaborating w. industrialised countries “ice breaking” when collaborating w. new partner countries putting “meat on the bones” of S+T agreements a sign of maturity of the FPs (openness) targets: OECD, all 3rd countries

International Collaboration -what is new in FP7? The management of thematic INCO projects moves from the INCO directorate to the thematic directorates  INCO-Health to Health Research -better synergies with traditional collaborative projects in the theme -greater visibility for INCO projects as part of a larger portfolio

International Collaboration in FP7 2 different avenues: 1. All activities open for International Cooperation International Cooperation Partner Countries (ICPCs) can participate in projects and receive EC funding Minimum number of participants: 3 from MS/AS 2. Specific International Cooperation Actions Address specific issues of partner countries or with a global character, on the basis of mutual interest and benefit Minimum number of participants: 2+2 (2 from MS/AS + 2 from ICPCs)

International Collaboration in FP7 Health Example of a SICA topics in the first Work Programme (deadlines in 2007) Childhood and adolescent mental disorders The research should be aimed at investigating paediatric mental disorders that have a high prevalence in countries of Central and Eastern Europe. The projects should use population genetics/genomics approaches and include bioinformatics/biostatistics to increase knowledge of the patterns of disease prevalence and develop possible diagnostic and therapeutic strategies as well as address prevention.

International Collaboration in FP7 Health Example of a SICA topics in the first Work Programme (deadlines in 2007) Epidemiological investigations into long-term trends of population health as consequence of socio-economic transitions, including life-style induced health problems Investigations into tackling the burden of chronic diseases such as diabetes, cardiovascular and liver diseases, for identifying strategies at the population level to implement effective solutions to improve health. Specific International Cooperation Action. Targeted regions: Mediterranean Partner countries, Russia, Eastern European and Central Asia.

International Collaboration in FP7 Health Other initiatives International activities in large scale data gathering for functional genomics -organising and coordinating endeavours aiming at collecting, integrating and curating genomics, proteomics, population genetics, comparative and functional genomics data and/or samples of relevance to human health

Collaborative Health research in FP7 SUMMARY Continuity in collaborative Health research to: develop new tools and technologies promote translational research optimise delivery of health care [ using usual FP funding mechanisms ] & A novel approach to improve drug development: The Innovative Medicines Initiative [ using the proposed Joint Technology Initiative in FP7 ]

Information EU research: http://ec.europa.eu/research Seventh Framework Programme: http://ec.europa.eu/research/fp7 Information on research programmes and projects: http://www.cordis.lu/ RTD info magazine: http://ec.europa.eu/research/rtdinfo/ Information requests: http://ec.europa.eu/research/enquiries/